Published • loading... • Updated
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
The multi-center study will enroll up to 135 patients and test safety, dosing and efficacy after earlier results showed an 83.3% disease control rate.
- On Thursday, South Korean biotechnology company SN BioScience Inc. initiated the first patient dosing in a global Phase 1b/2 clinical trial evaluating SNB-101 for Extensive-Stage Small Cell Lung Cancer , enrolling up to 135 patients across sites in the United States and Europe.
- Prior Phase 1 results conducted in Korea support the advancement, demonstrating a favorable safety profile with an 83.3% disease control rate and mean progression-free survival of 6.3 months in SCLC patients.
- The U.S. Food and Drug Administration granted SNB-101 Fast Track Designation, while Orphan Drug Designation from the FDA and European Medicines Agency establishes the regulatory framework for pursuing accelerated approval.
- SN BioScience obtained EMA approval to evaluate SNB-101 in combination with an immunotherapy agent and plans to submit a Clinical Trial Application for a separate combination study within this year.
- Expanding beyond SCLC, the company is pursuing SNB-101 development for additional solid tumor indications, including gastric and pancreatic cancers, through ongoing collaborations with global pharmaceutical companies.
Insights by Ground AI
36 Articles
36 Articles
keenesentinel.com+35 Reposted by 35 other sources
SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'
SEONGNAM, South Korea, May 14, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38),…
Coverage Details
Total News Sources36
Leaning Left7Leaning Right4Center10Last UpdatedBias Distribution48% Center
Bias Distribution
- 48% of the sources are Center
48% Center
L 33%
C 48%
R 19%
Factuality
To view factuality data please Upgrade to Premium
